A detailed history of Susquehanna International Group, LLP transactions in Abeona Therapeutics Inc. stock. As of the latest transaction made, Susquehanna International Group, LLP holds 47,563 shares of ABEO stock, worth $280,146. This represents 0.0% of its overall portfolio holdings.

Number of Shares
47,563
Previous 27,466 73.17%
Holding current value
$280,146
Previous $199,000 1.01%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 15, 2024

BUY
$3.17 - $8.05 $63,707 - $161,780
20,097 Added 73.17%
47,563 $201,000
Q1 2024

May 07, 2024

SELL
$4.07 - $8.68 $55,734 - $118,863
-13,694 Reduced 33.27%
27,466 $199,000
Q4 2023

Feb 14, 2024

SELL
$3.71 - $5.14 $102,830 - $142,465
-27,717 Reduced 40.24%
41,160 $206,000
Q3 2023

Nov 14, 2023

BUY
$2.98 - $4.43 $205,253 - $305,125
68,877 New
68,877 $289,000

Others Institutions Holding ABEO

About ABEONA THERAPEUTICS INC.


  • Ticker ABEO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 5,950,380
  • Market Cap $35M
  • Description
  • Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-a...
More about ABEO
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.